Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase III Cat-PAD Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01620762
Recruitment Status : Completed
First Posted : June 15, 2012
Results First Posted : May 14, 2018
Last Update Posted : June 15, 2018
Sponsor:
Collaborators:
inVentiv Health Clinical
Pharm-Olam International
Information provided by (Responsible Party):
Circassia Limited

Brief Summary:
The purpose of this study is to compare the treatment effect of two treatment regimens of Cat-PAD vs placebo and to evaluates the treatment effect of Cat-PAD on symptoms, rescue medication usage and Quality of Life.

Condition or disease Intervention/treatment Phase
Rhinoconjunctivitis Drug: Cat-PAD Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1408 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Randomised, Placebo-Controlled Multi-Centre Field Study to Assess the Efficacy and Safety of Cat-PAD Peptide Immunotherapy in Cat Allergic Subjects
Study Start Date : October 2012
Actual Primary Completion Date : June 2016

Arm Intervention/treatment
Experimental: Cat-Pad Treatment 1
Cat-PAD Treatment 1
Drug: Cat-PAD
1 dose every 4 weeks

Experimental: Cat-PAD Treatment 2
Cat-PAD Treatment regimen 2
Drug: Cat-PAD
1 dose every 4 weeks

Drug: Placebo
1 dose every 4 weeks

Placebo Comparator: Placebo
Placebo
Drug: Placebo
1 dose every 4 weeks




Primary Outcome Measures :
  1. Mean Combined Score in Cat-PAD Treatment Groups Compared With Placebo [ Time Frame: 52-54 weeks after randomisation ]

    The primary endpoint was the mean Combined Score (CS) measured over a 3 week period (52-54 weeks after randomisation) in the Cat-PAD treatment groups compared with the mean CS in the placebo group. A higher score indicated worse symptoms or greater use of medication and thus a low score indicated a better outcome.

    CS = Total Rhinoconjunctivitis Symptom Score (TRSS) + Rescue Medication Score (RMS). Eight symptoms are defined in the TRSS, 4 nasal symptoms: runny nose, sneezing; blocked nose, and itchy nose and 4 ocular symptoms: itchy eyes; watery eyes; red eyes and sore eyes. Each symptom was rated in severity on a score of 0-3 (0=absent, 3=severe) and the total was divided by the number of symptoms to provide an average score per symptom of 0-3.

    RMS was scored from 0 (no allergy rescue medication use per day) to 3 (at least one dose of systemic corticosteroid per day). The RMS score was not additive, and therefore the maximum RMS was 3 and the maximum CS was 6.



Secondary Outcome Measures :
  1. Mean TRSS [ Time Frame: 52-54 weeks after randomisation ]

    Mean Total Rhinoconjunctivitis Symptom Score (TRSS) in Cat-PAD treatment groups compared with placebo.

    Eight symptoms are defined in the TRSS, 4 nasal symptoms: runny nose, sneezing; blocked nose, and itchy nose and 4 ocular symptoms: itchy eyes; watery eyes; red eyes, and sore eyes. Each symptom was rated in severity on a score of 0-3 (0. absent; 1. mild, barely noticeable; 2. moderate, annoying/troublesome; 3. severe, very annoying/very troublesome), therefore TRSS could range from 0 to 24. Higher TRSS reflected more severe symptom scores. Symptoms were scored daily for a period of approximately 3 weeks. 52-54 weeks after randomisation.


  2. Mean Daily TNSS in Cat-PAD Compared With Placebo [ Time Frame: 52-54 weeks after randomisation ]

    TNSS (Total nasal symptom score) was the sum of all the nasal symptom scores (runny nose; sneezing; blocked nose; itchy nose) and could range from 0 to 12. Higher TNSS reflected more severe symptoms.

    Subjects rated the severity of each symptom over the last 24 hours as follows: 0. absent; 1. mild, barely noticeable; 2. moderate, annoying/troublesome; 3. severe, very annoying/very troublesome. Symptoms were scored daily for a period of approximately 3 weeks. 52-54 weeks after randomisation.


  3. Mean Daily TOSS in Cat-PAD Compared to Placebo [ Time Frame: 52-54 weeks after randomisation ]

    Mean daily Total Ocular Symptom Score (TOSS) in Cat-PAD treatment groups compared to placebo groups

    TOSS was the sum of all the ocular symptom scores (itchy eyes; watery eyes; red eyes; sore eyes) and could range from 0 to 12. Higher TOSS reflected more severe symptoms.

    Subjects rated the severity of each symptom over the last 24 hours as follows: 0. absent; 1. mild, barely noticeable; 2. moderate, annoying/troublesome; 3. severe, very annoying/very troublesome. Symptoms were scored daily for a period of approximately 3 weeks. 52-54 weeks after randomisation.


  4. Mean RMS in Cat-PAD Compared With Placebo [ Time Frame: 52-54 weeks after randomisation ]

    Mean RMS (Rescue medication score) in Cat-PAD treatment groups compared with placebo groups.

    The use of rhinoconjunctivitis rescue medications was recorded by the subject on a daily basis just before bedtime for approximately 21 days, 52-54 weeks after randomisation and was scored based on a previously published system as follows: 0 = no allergy rescue medication used per day; 0.5 = at least one dose of antihistamine eye drops used per day; 1 = at least one dose of oral antihistamine used per day; 2 = at least one dose of intranasal corticosteroid used per day; 3 = at least one dose of systemic corticosteroid used per day. The score was according to the highest level of rescue medication used and was not additive.


  5. Mean RQLQ Score in Cat-PAD Compared With Placebo [ Time Frame: 52-54 weeks after randomisation ]

    The RQLQ (Rhinoconjunctivitis Quality of Life Questionnaire) was completed by subjects at the end of the study (52-54 weeks after randomisation).

    The RQLQ is a validated method of assessing quality of life and has 28 questions in seven domains (activity limitation, sleep problems, nasal symptoms, eye symptoms, non-nasal/eye symptoms, practical problems and emotional function). Subjects recalled how their rhinoconjunctivitis had been during the last week and responded to each question on a seven-point scale (0 = no impairment, 6 = maximum impairment). The questions were equally weighted, and the RQLQ score was the mean of the 28 questions and could range from zero to six.


  6. Number of Days With no Moderate or Severe TRSS Symptoms Without Rescue Medication Use [ Time Frame: 52-54 week after randomisaiton ]
    The number of well days, i.e., days with no moderately or severely annoying symptoms and with no rescue medication used was calculated for all subjects over a period of approximately 21 days, 52-54 weeks after randomisation.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years to 65 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Male or female, aged 12-65 years.
  • Moderate to severe rhinoconjunctivitis on exposure to cats for at least 2 years.
  • Subjects may optionally also have GINA Step 1 controlled asthma.
  • Positive skin prick test to cat hair.
  • Cat dander specific IgE ≥0.35 kU/L.

Exclusion Criteria

  • Asthma falling under the GINA definitions "partly controlled" and "uncontrolled" or Steps 2 to 5.
  • FEV1 <80% of predicted.
  • Clinically significant confounding symptoms of allergy to seasonal allergens during the final evaluation period.
  • Skin prick test 5 mm greater than the negative control to perennial allergens or animal dander (other than cat) which cannot be avoided during the study.
  • Significant symptoms of another clinically relevant illness that is likely to affect scoring of rhinoconjunctivitis symptoms.
  • Clinically relevant abnormalities detected on physical examination.
  • History of severe drug allergy, severe angioedema or anaphylactic reaction to food.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01620762


Locations
Hide Hide 118 study locations
Layout table for location information
United States, California
Rolling Hills Estates, California, United States
United States, Colorado
Colorado Springs, Colorado, United States
Denver, Colorado, United States
Wheat Ridge, Colorado, United States
United States, Idaho
Eagle, Idaho, United States
Meridian, Idaho, United States
United States, Illinois
Chicago, Illinois, United States
Evanston, Illinois, United States
Forrest, Illinois, United States
Normal, Illinois, United States
United States, Iowa
Iowa, Iowa, United States
United States, Kansas
Overland Park, Kansas, United States
United States, Maine
Bangor, Maine, United States
United States, Massachusetts
Brockton, Massachusetts, United States
United States, Michigan
Ypsilanti, Michigan, United States
United States, Minnesota
Minneapolis, Minnesota, United States
United States, Missouri
Kansas City, Missouri, United States
Saint Louis, Missouri, United States
United States, Montana
Bozeman, Montana, United States
Missoula, Montana, United States
United States, Nebraska
Bellevue, Nebraska, United States
Fremont, Nebraska, United States
Omaha, Nebraska, United States
United States, New Jersey
Ocean Township, New Jersey, United States
United States, New Mexico
Albuquerque, New Mexico, United States
United States, New York
Corning, New York, United States
Newburgh, New York, United States
United States, North Dakota
Fargo, North Dakota, United States
Minot, North Dakota, United States
United States, Ohio
Canton, Ohio, United States
Cincinnati, Ohio, United States
Middleburg Heights, Ohio, United States
Sylvania, Ohio, United States
Toledo, Ohio, United States
United States, Oklahoma
Tulsa, Oklahoma, United States
United States, Oregon
Lake Oswego, Oregon, United States
Medford, Oregon, United States
Portland, Oregon, United States
United States, Pennsylvania
Blue Bell, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
United States, Tennessee
Germantown, Tennessee, United States
Nashville, Tennessee, United States
United States, Texas
Dallas, Texas, United States
San Antonio, Texas, United States
United States, Utah
Draper, Utah, United States
United States, Virginia
Glen Allen, Virginia, United States
South Burlington, Virginia, United States
Warrenton, Virginia, United States
United States, Washington
Spokane, Washington, United States
United States, Wisconsin
Greenfield, Wisconsin, United States
Madison, Wisconsin, United States
Milwaukee, Wisconsin, United States
Belgium
Brussels, Belgium
Gent, Belgium
Leuven, Belgium
Canada, Ontario
Burlington, Ontario, Canada
Corruna, Ontario, Canada
Hamilton, Ontario, Canada
Kanata, Ontario, Canada
London, Ontario, Canada
Newmarket, Ontario, Canada
Niagara Falls, Ontario, Canada
Oshawa, Ontario, Canada
Ottawa, Ontario, Canada
Toronto, Ontario, Canada
Canada, Quebec
Montreal, Quebec, Canada
Pointe Claire, Quebec, Canada
Quebec City, Quebec, Canada
Trois Rivieres, Quebec, Canada
Czechia
Brnho, Czechia
Caslav, Czechia
Jablonec nad Nisou, Czechia
Kutna Hora, Czechia
Prague, Czechia
Rychnov nad Kneznou, Czechia
České Budějovice, Czechia
Germany
Berlin, Germany
Bonn, Germany
Bramsche, Germany
Hamburg, Germany
Heidelberg, Germany
Koln, Germany
Monchengladbach, Germany
Munster, Germany
München, Germany
Neuss, Germany
Osnabruck, Germany
Wesel, Germany
Wiesbaden, Germany
Wuppertal, Germany
Hungary
Budapest, Hungary
Csorna, Hungary
Pecs, Hungary
Tatabanya, Hungary
Poland
Bydgoszcz, Poland
Gdansk, Poland
Katowice, Poland
Krakow, Poland
Lodz, Poland
Lublin, Poland
Poznan, Poland
Rzeszow, Poland
Tarnow, Poland
Warszawa, Poland
Wroclaw, Poland
Zabrze, Poland
Zawadzkie, Poland
Russian Federation
Barnaul, Russian Federation
Moscow, Russian Federation
Novosibirsk, Russian Federation
Omsk, Russian Federation
Saint-Petersburg, Russian Federation
Stavropol, Russian Federation
Tomsk, Russian Federation
Yekaterinburg, Russian Federation
Slovakia
Bardejov, Slovakia
Martin, Slovakia
Poprad, Slovakia
Sponsors and Collaborators
Circassia Limited
inVentiv Health Clinical
Pharm-Olam International
Investigators
Layout table for investigator information
Principal Investigator: Harold Nelson, MD Jewish National Health
Layout table for additonal information
Responsible Party: Circassia Limited
ClinicalTrials.gov Identifier: NCT01620762    
Other Study ID Numbers: CP007
First Posted: June 15, 2012    Key Record Dates
Results First Posted: May 14, 2018
Last Update Posted: June 15, 2018
Last Verified: May 2018
Keywords provided by Circassia Limited:
Cat allergy
Rhinoconjunctivitis
Additional relevant MeSH terms:
Layout table for MeSH terms
Conjunctivitis
Conjunctival Diseases
Eye Diseases